Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Texas Biotechnology and Synthelabo enter new argatroban collaboration

June 28, 1996

BCH-2763: BioChem Therapeutic's novel thrombin inhibitor

June 28, 1996

Nippon Mining reports on HV1C3

June 28, 1996

FDA approval of new indication for Genentech's Activase

June 21, 1996

LM-AS-013 development for peripheral vascular disorders terminated

June 21, 1996

E. Merck reports fibrinogen (gpIIb/IIIa) antagonists

June 21, 1996

Mitsubishi Chem.'s Novastan receives Japanese approval for new indication

June 21, 1996

Modified factor VII described for coagulation-related disorders

June 21, 1996

A02131-1: Novel PDE V inhibitor

June 14, 1996

Corvas reveals anticoagulant proteins

June 14, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...